Coherus Oncology (CHRS) Gross Profit (2019 - 2026)
Coherus Oncology (CHRS) posted Gross Profit of $8.5 million for Q1 2026, down 2.38% sequentially from $8.7 million in Q4 2025, and up 71.78% YoY from $4.9 million in Q1 2025.
Coherus Oncology (CHRS) Gross Profit (2019 - 2026) Analysis & Trends
Coherus Oncology has reported Gross Profit for 8 years, with the latest figure at $8.5 million in Q1 2026.
- Quarterly Gross Profit rose 71.78% year-over-year to $8.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $31.9 million (up 46.78% YoY) and the FY2025 annual result came in at $28.4 million, up 60.56% from the prior year.
- Gross Profit eased to $8.5 million in Q1 2026 per CHRS's latest filing, from $8.7 million in the prior quarter.
- Over five years, Gross Profit peaked at $50.7 million in Q1 2022 and troughed at $869000.0 in Q1 2024.
- A 5-year average of $17.3 million and a median of $8.5 million in 2026 frame the typical range for Gross Profit.
- The sharpest annual moves came in 2024 and 2025: Gross Profit plunged 94.42% in 2024, then surged 469.16% in 2025.
- Over 5 years, Gross Profit stood at $31.2 million in 2022, then sank by 77.67% to $7.0 million in 2023, then dropped by 28.37% to $5.0 million in 2024, then soared by 74.65% to $8.7 million in 2025, then retreated by 2.38% to $8.5 million in 2026.
- According to Business Quant data, Gross Profit over the past three periods registered $8.5 million, $8.7 million, and $7.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Coherus Oncology | 221.39 Mn | 116.08 Mn | 10.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.07 Mn |
| Jun 30, 2026 | 10.07 Mn |
| Mar 31, 2026 | 8.50 Mn |
| Mar 31, 2026 | 8.50 Mn |
| Dec 31, 2025 | 8.70 Mn |
| Dec 31, 2025 | 8.70 Mn |
| Sep 30, 2025 | 7.85 Mn |
| Sep 30, 2025 | 7.85 Mn |
| Jun 30, 2025 | 6.86 Mn |
| Jun 30, 2025 | 6.86 Mn |
| Mar 31, 2025 | 4.95 Mn |
| Mar 31, 2025 | 4.95 Mn |
| Dec 31, 2024 | 4.98 Mn |
| Dec 31, 2024 | 4.98 Mn |
| Sep 30, 2024 | 3.32 Mn |
| Sep 30, 2024 | 3.32 Mn |
| Jun 30, 2024 | 8.49 Mn |
| Jun 30, 2024 | 8.49 Mn |
| Mar 31, 2024 | 869,000.00 |
| Mar 31, 2024 | 869,000.00 |